A Study of JNJ-68179280 in Healthy Participants

NCT04844463 | Completed Phase 1 FDA Drug

• 2 other identifiers: CR10898968179280IBD1001
• Study Type: interventional
• Target: 94
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of JNJ-68179280 compared with placebo after administration of single ascending oral doses of JNJ-68179280 administered to healthy participants (Part 1), multiple ascending oral doses of JNJ-68179280, administered to healthy participants once daily (Cohorts 1 through 4) or twice daily (Cohort 5) over 14 consecutive days (Part 2) and multiple ascending oral doses of an alternative JNJ-68179280 formulation, administered to healthy participants once daily over 14 consecutive days (Part 3 if conducted).

Conditions

Healthy

Outcome Measures

Primary Outcomes (6)

• Number of Participants with Treatment-emergent Adverse Events (TEAEs)

  An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

  Up to 35 days

• Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)

  SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

  Up to 35 days

• Number of Participants with Clinically Significant Abnormalities in Vital Signs

  Number of participants with clinically significant abnormalities in vital signs (including temperature \[oral or tympanic\], pulse/heart rate, respiratory rate, and blood pressure) will be reported.

  Up to 35 days

• Number of Participants with Clinically Significant Abnormalities in Physical Examination

  Number of participants with clinically significant abnormalities in physical examination (including general appearance, respiratory, cardiovascular, assessment through skin or oral mucosa) will be reported.

  Up to 35 days

• Number of Participants with Clinically Significant Abnormalities in Laboratory Safety Tests

  Number of participants with clinically significant abnormalities in laboratory safety tests (such as serum chemistry, hematology and urinalysis) will be reported.

  Up to 35 days

• Number of Participants with Clinically Significant Abnormalities in 12-lead Electrocardiograms (ECGs)

  Number of participants with clinically significant abnormalities in ECGs will be reported.

  Up to 28 days

Secondary Outcomes (19)

• Part 1, 2 and 3: Plasma Concentration of JNJ-68179280

  Up to 19 days

• Part 1, 2 and 3: Urine Concentration of JNJ-68179280

  Up to 19 days

• Part 1, 2 and 3: Stool Concentration of JNJ-68179280

  Up to 16 days

• Part 1: Plasma Concentration of JNJ-68179280 Under Fasted Condition

  Up to Day 6

• Part 1: Plasma Concentration of JNJ-68179280 Under Fed Condition

  Up to 13 days

Study Arms (3)

Part 1: Single Ascending Dose (SAD)

EXPERIMENTAL

Participants will receive a single ascending oral dose of JNJ-68179280 or placebo capsules under fasted condition (Cohort 1, 2 and 5) and under fasted-fed condition (either Cohort 3 or 4) on Day 1. In 1 of the study cohorts 3 or 4, participants will also receive study intervention on Day 8 under fed condition. One additional optional Cohort 6 may be dosed to assess the safety and pharmacokinetics (PK) of an alternate dose of formulation A under fasted condition.

Drug: JNJ-68179280; Other: Placebo

Part 2: Multiple Ascending Dose (MAD)

EXPERIMENTAL

Participants will receive multiple ascending oral doses of JNJ-68179280 or placebo capsules once daily in Cohort 1 through 4 or twice daily in Cohort 5 (optional) on Days 1 through 14 under fasted or fed condition.

Drug: JNJ-68179280; Other: Placebo

Part 3: Multiple Dose Alternative Formulation (Optional)

EXPERIMENTAL

Participants will receive multiple oral doses of an alternative JNJ-68179280 formulation once daily in Cohort 1 and Cohort 2 (optional) on Days 1 through 14 under fasted or fed condition. Doses in Part 3 will depend on the safety, tolerability, PK and pharmacodynamics data from Part 1 and Part 2.

Drug: JNJ-68179280

Interventions

JNJ-68179280 DRUG

JNJ-68179280 will be administered as an oral capsule.

Part 1: Single Ascending Dose (SAD); Part 2: Multiple Ascending Dose (MAD); Part 3: Multiple Dose Alternative Formulation (Optional)

Placebo OTHER

Matching placebo will be administered as an oral capsule.

Part 1: Single Ascending Dose (SAD); Part 2: Multiple Ascending Dose (MAD)

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy on the basis of physical examination, medical history, vital signs, and 12 lead electrocardiogram (ECG) performed at screening. Any abnormalities must be considered not clinically significant and this determination must be recorded in the participant's source documents and initialed by the investigator
• Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel (excluding liver enzymes) including hematology, blood coagulation, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
• Have the following pre study intervention clinical laboratory values during screening and check-in to the unit (Day -2 or Day -1): a. aspartate transaminase (AST) less than or equal to (\<=) upper limit of normal (ULN), b. alanine aminotransferase (ALT) \<= ULN, c. bilirubin \<= ULN, d. alkaline phosphatase \<= ULN, e. gamma-glutamyl transpeptidase (GGTP) \<= ULN, f. albumin greater than or equal to (\>=) lower limit of normal (LLN)
• A woman must have a negative highly sensitive serum beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at check-in to the unit on Day -2 or Day -1
• Must be a non-smoker (not smoked for at least 6 months prior to screening) and has not used nicotine-containing products (example: nicotine patch, vaping, hookah) for 3 months prior to screening

You may not qualify if:

• History of liver or renal insufficiency significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• History of malignancy before screening (exceptions are squamous or basal cell carcinomas of the skin and carcinoma in situ of the cervix as long as they are considered cured with minimal risk of recurrence)
• Has an active, acute or chronic infection
• Has taken any disallowed therapies, concomitant therapy before the planned first dose of study intervention
• Has a positive urine drug screen and/or alcohol breath test during screening or on Day 2

Sponsors & Collaborators

• Janssen Research & Development, LLC: lead

Study Sites (1)

Celerion

Lincoln, Nebraska, 68502, United States

Location

Study Officials

• Janssen Research & Development, LLC Clinical Trial

  Janssen Research & Development, LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2021
• First Posted: April 14, 2021
• Study Start: May 26, 2021
• Primary Completion: March 7, 2023
• Study Completion: March 13, 2023
• Last Updated: February 3, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will share

Locations

US (1)